Contreras-Kallens P, Gálvez-Jirón F, De Solminihac J, et al. — Frontiers in Oncology, 2022
This study investigates the role of regulatory T-cell subsets in the tumor microenvironment, with particular emphasis on Type 1 regulatory T cells (Tr1 cells), and evaluates the CD49b/CD29 integrin axis as a potential therapeutic target in cancer. Although conventional Foxp3+ regulatory T cells (cTregs) are well recognized for suppressing anti-tumor immunity, considerably less is known about Foxp3− Tr1 cells and their contribution to tumor-associated immunosuppression. The authors therefore compared these populations in murine tumor models and tested whether interfering with CD49b/CD29 signaling could enhance anti-tumor responses.
For the study, cTregs were defined as CD4+Foxp3+CD49b− cells and Tr1 cells as CD4+Foxp3−CD49b+ cells. Using a B16 melanoma model in Foxp3-GFP reporter mice, the researchers analyzed these populations in tumor-draining lymph nodes (TdLNs) and among tumor-infiltrating leukocytes (TILs). Flow cytometry, BrdU incorporation and viSNE analysis were used to characterize their abundance, proliferation, cytokine production and expression of regulatory markers. Additional experiments tested an anti-CD29 antibody in B16 melanoma, MB49 urothelial carcinoma and EL-4 lymphoma models.
One of the central findings was the remarkable accumulation of Tr1 cells within tumors. While Tr1 cells represented 5% or less of CD4+ T cells in naïve and tumor-draining lymph nodes, they accounted for almost 30% of CD4+ T cells among TILs. Conventional Tregs were also enriched in tumors, but to a lesser extent, reaching approximately 20%. Moreover, Tr1 cells appeared very early during tumor development: they represented around 20% of tumor-infiltrating CD4+ cells during the first week and increased to approximately 30% by week three.
Interestingly, this accumulation was not explained by increased Tr1 proliferation. BrdU experiments showed that cTregs were substantially more proliferative than Tr1 cells within tumors. More than 30% of BrdU+ cells corresponded to cTregs, compared with only approximately 5% for Tr1 cells. The authors therefore suggest that mechanisms such as recruitment from lymph nodes or local differentiation, rather than proliferation, may account for the high abundance of tumor-associated Tr1 cells.
Phenotypically, tumor-associated Tr1 cells displayed several features associated with immunosuppressive activity, including expression of Nrp-1, PD-1 and CD73. Their phenotype differed according to anatomical location, suggesting that the tumor microenvironment influences their regulatory properties. Particularly notable was the high frequency of CD73+ Tr1 cells in TILs, approaching 90%, and the increased production of IL-10 by Tr1 cells compared with cTregs. viSNE analysis further supported the interpretation that cTregs and Tr1 cells constitute distinct regulatory populations.
Based on the strong presence of CD49b+ Tr1 cells in tumors, the researchers then investigated the CD49b/CD29 axis. CD49b forms the α2β1 integrin together with CD29, participating in processes such as cell adhesion, migration and T-cell signaling. Rather than directly targeting CD49b—which is also widely expressed by platelets and NK cells—the researchers administered an antibody against its β1 partner, CD29.
Anti-CD29 treatment produced a striking inhibition of tumor growth in the B16 melanoma model and also strongly inhibited MB49 tumor growth. In contrast, it had no significant effect on EL-4 lymphoma. Importantly, the tumor cell lines differed in their expression of the targeted molecules: approximately 40% of B16 and 80% of MB49 cells expressed CD49b, while around 90% of both expressed CD29. EL-4 cells essentially lacked both markers. This association suggests that expression of CD49b/CD29 by tumor cells may contribute to the response to treatment.
The anti-tumor effect was accompanied not by elimination of regulatory T-cell populations, but by a shift in their functional phenotype toward a more inflammatory state. Following anti-CD29 treatment, the proportions of cTregs and Tr1 cells remained largely unchanged, but both populations showed increased IFN-γ and reduced IL-10 expression. Within tumors, IFN-γ+ cTregs increased from approximately 15% to 30%, while IFN-γ+ Tr1 cells increased from approximately 15% to 25%. IL-10 expression decreased in both populations, and tumor-infiltrating cTregs also displayed increased granzyme B. f
Effector T cells were also affected. Anti-CD29-treated tumors contained higher frequencies of IFN-γ-producing and granzyme B-producing CD8+ T cells, indicating enhanced cytotoxic and pro-inflammatory activity. Critically, anti-CD29 failed to produce an anti-tumor effect in RAG-deficient mice lacking functional B- and T-cell responses. This finding indicates that the treatment’s tumor-inhibitory effect depends substantially on adaptive immunity rather than simply exerting direct toxicity against cancer cells.
To explore potential relevance to human cancer, the authors analyzed publicly available RNA-sequencing datasets from melanoma, bladder cancer and lymphoma. CD29 expression increased with melanoma progression, whereas bladder cancer and lymphoma samples showed CD29 expression in some individuals without a clear stage-dependent pattern. The authors consequently identify CD29 as a potential immunotherapeutic target while emphasizing that additional analyses of gene and protein expression across human tumor types and stages are required.
Overall, the study expands the conventional view of regulatory T cells in cancer by demonstrating that Tr1 cells constitute a substantial and early component of the immunosuppressive tumor microenvironment. Disrupting the CD49b/CD29 axis with anti-CD29 antibodies markedly inhibited melanoma and urothelial tumor growth in mice, while shifting regulatory and effector T cells toward a more pro-inflammatory, anti-tumor phenotype. Rather than simply depleting Tregs, CD29 targeting appears to modify the functional balance of the immune response. The results therefore identify the CD49b/CD29 pathway—and CD29 in particular—as a promising candidate for further investigation in cancer immunotherapy, although the evidence presented is primarily preclinical and additional studies are required to determine its applicability to human cancers.